AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32723341 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted patient reported experience tool
Number of subjects: 600
Study 32723388 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter engagement through @ELFStudy
Number of subjects: 952
Study 32723525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 42
Study 32723590 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific dementia risk score (DSDRS)
Number of subjects: 2241
Study 32723735 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with the highest probabilities for progression
Number of subjects: 297
Study 32723735 — intervention group
Group type: COMPARATOR
Intervention: Patients with lower probabilities for progression
Number of subjects: 297
Study 32723990 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma medication adherence assessment through patient interviews using four questions from the Malaysian Medication Adherence Scale.
Number of subjects: 1011
Study 32723990 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of asthma control using the Global Initiative for Asthma (GINA) Assessment of Symptom Control.
Number of subjects: 1011
Study 32724669 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT imaging
Number of subjects: 3631
Study 32724669 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-monitored patients (≥8 OCT examinations)
Number of subjects: 3631
Study 32724669 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of OCT and fluorescein angiography imaging
Number of subjects: 3631
Study 32725443 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated radiotherapy (RT) with simultaneous boost to the intraprostatic lesion
Number of subjects: 65
Study 32725444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120 mg at extended dosing intervals (>4 weeks)
Number of subjects: 109
Study 32725991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFR (≤2) in high FFR group
Number of subjects: 867
Study 32725991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFR (≤2) in low FFR group
Number of subjects: 867
Study 32725991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFR (≤2) and high IMR (≥23 U) in high FFR group
Number of subjects: 867
Study 32725991 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt microvascular disease in high FFR group
Number of subjects: 867
Study 32726419 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (400-1200 mg twice daily)
Number of subjects: 239
Study 32726447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime Engagement Scale (MES)
Number of subjects: 18
Study 32726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% emollient foam applied daily
Number of subjects: 30
Study 32726560 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in cord blood
Number of subjects: 0
Study 32726602 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (anti-ferroptotic iron chelator)
Number of subjects: 0
Study 32726602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing larger multi-centre phase 2 clinical trial of deferiprone
Number of subjects: 0
Study 32727600 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural History Study (NHS) of FOP
Number of subjects: 114
Study 32727600 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiograms from 22 patients with FOP
Number of subjects: 114
Study 32727853 — intervention group
Group type: COMPARATOR
Intervention: Primary microvascular angina (MVA)
Number of subjects: 50
Study 32727853 — intervention group
Group type: COMPARATOR
Intervention: Takotsubo syndrome (TTS)
Number of subjects: 50
Study 32728218 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA vaccine
Number of subjects: 0
Study 32728218 — intervention group
Group type: COMPARATOR
Intervention: Checkpoint inhibitor treatment
Number of subjects: 0
Study 32728595 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8601 (synthetic mRNA encoding VEGF-A)
Number of subjects: 0
Study 32728595 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32728832 — intervention group
Group type: COMPARATOR
Intervention: Mealtime ultra-rapid lispro (URLi)
Number of subjects: 167
Study 32728832 — intervention group
Group type: COMPARATOR
Intervention: Postmeal ultra-rapid lispro (URLi)
Number of subjects: 167
Study 32728832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime and postmeal ultra-rapid lispro (URLi)
Number of subjects: 167
Study 32728833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi)
Number of subjects: 93
Study 32728833 — intervention group
Group type: COMPARATOR
Intervention: Lispro
Number of subjects: 93
Study 32728839 — intervention group
Group type: EXPERIMENTAL
Intervention: Social jet lag (SJL)
Number of subjects: 122
Study 32728880 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet (fat intake: saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA))
Number of subjects: 73
Study 32728880 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intestinal markers (zonulin, intestinal alkaline phosphatase activity, faecal calprotectin)
Number of subjects: 73
Study 32728965 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 742
Study 32729929 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab at 3 mg/kg and Ipilimumab at 1 mg/kg every 3 weeks for 4 doses, followed by Nivolumab 3 mg/kg every 2 weeks for up to 96 weeks.
Number of subjects: 39
Study 32730119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV) - 4 doses
Number of subjects: 825
Study 32730119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed PCV10 + PCV13 schedule
Number of subjects: 825
Study 32730119 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 825
Study 32730186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 39
Study 32730187 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) after reinduction chemotherapy for very high risk and high risk patients.
Number of subjects: 116
Study 32730187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine monotherapy for low risk patients (CD3-negative relapse > 1 year after initial diagnosis).
Number of subjects: 116
Study 32730187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine monotherapy for intermediate risk patients after termination of autologous SCT.
Number of subjects: 116
Study 32730187 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT for intermediate risk patients (prior to termination).
Number of subjects: 116
Study 32730187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine monotherapy for early relapses.
Number of subjects: 116
Study 32730187 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT for early relapses.
Number of subjects: 116
Study 32730187 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic SCT for high-risk ALCL relapse.
Number of subjects: 116
Study 32730305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status (measured by mini-nutritional assessment scale, total protein levels, CRP)
Number of subjects: 113
Study 32730305 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-energy wasting
Number of subjects: 113
Study 32730305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status
Number of subjects: 113
Study 32730586 — intervention group
Group type: EXPERIMENTAL
Intervention: AFM13 in combination with pembrolizumab
Number of subjects: 0
Study 32730586 — intervention group
Group type: COMPARATOR
Intervention: AFM13
Number of subjects: 0
Study 32730586 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab
Number of subjects: 0
Study 32730756 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive to HIV-positive kidney and liver transplantation
Number of subjects: 22
Study 32731102 — intervention group
Group type: EXPERIMENTAL
Intervention: Core body temperature (CBT) measurements in patients with sepsis (n=12)
Number of subjects: 33
Study 32731102 — intervention group
Group type: COMPARATOR
Intervention: Core body temperature (CBT) measurements in patients without sepsis
Number of subjects: 33
Study 32731841 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE)
Number of subjects: 97
Study 32731841 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography colonography (CTC)
Number of subjects: 97
Study 32732023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypophosphataemia (phosphataemia below 0.8 mmol/L)
Number of subjects: 193
Study 32732023 — intervention group
Group type: COMPARATOR
Intervention: Patients without hypophosphataemia
Number of subjects: 193
Study 32732224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination targeting HER2Δ16
Number of subjects: 0
Study 32732224 — intervention group
Group type: COMPARATOR
Intervention: Vaccines targeting a nondriver tumor-specific antigen or tumor neoepitopes
Number of subjects: 0
Study 32732303 — intervention group
Group type: EXPERIMENTAL
Intervention: ADNEX with CA125
Number of subjects: 5717
Study 32732303 — intervention group
Group type: EXPERIMENTAL
Intervention: ADNEX without CA125
Number of subjects: 5717
Study 32732303 — intervention group
Group type: EXPERIMENTAL
Intervention: SRRisk
Number of subjects: 5717
Study 32732303 — intervention group
Group type: EXPERIMENTAL
Intervention: RMI
Number of subjects: 5717
Study 32732303 — intervention group
Group type: EXPERIMENTAL
Intervention: ADNEX models and SRRisk
Number of subjects: 5717
Study 32732318 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with CHD
Number of subjects: 709
Study 32732318 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 709
Study 32732355 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel
Number of subjects: 31
Study 32732380 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) or umbilical cord milking (UCM)
Number of subjects: 3116
Study 32733187 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive sensory feedback system
Number of subjects: 7
Study 32733232 — intervention group
Group type: EXPERIMENTAL
Intervention: Real/Real group (rTMS + cognitive training)
Number of subjects: 34
Study 32733232 — intervention group
Group type: COMPARATOR
Intervention: Sham/Sham group (control)
Number of subjects: 34
Study 32733232 — intervention group
Group type: COMPARATOR
Intervention: Real/Sham group (rTMS only)
Number of subjects: 34
Study 32733577 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatments combined with acupuncture therapy (electroacupuncture and scalp acupuncture) for a median course of five months
Number of subjects: 315
Study 32733577 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatments combined with acupuncture therapy
Number of subjects: 315
Study 32733600 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 160/80 mg at weeks 0/2 and 40 mg at weeks 4/6
Number of subjects: 205
Study 32733600 — intervention group
Group type: COMPARATOR
Intervention: Placebo at weeks 0/2 followed by adalimumab 160/80 mg at weeks 4/6
Number of subjects: 205
Study 32733606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal pemetrexed (IP) combined with involved-field radiotherapy (IFRT)
Number of subjects: 34
Study 32733900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0
Study 32733900 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Number of subjects: 0
Study 32733900 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32733902 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota analysis in critically ill patients after cardiovascular surgery with sepsis
Number of subjects: 0
Study 32733902 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiota analysis in critically ill patients after cardiovascular surgery without sepsis
Number of subjects: 0
Study 32734176 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral rotavirus vaccine
Number of subjects: 0
Study 32734200 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic patient decision support tool
Number of subjects: 70
Study 32734204 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD registry with point-of-care notifications and quarterly feedback for 12 months
Number of subjects: 137
Study 32734204 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD self-management support program for 12 months
Number of subjects: 137
Study 32734204 — intervention group
Group type: COMPARATOR
Intervention: Usual care registry for 12 months
Number of subjects: 137
Study 32734204 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 12 months
Number of subjects: 137
Study 32734207 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa-epbx
Number of subjects: 1425
Study 32734207 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 1425
Study 32734207 — intervention group
Group type: COMPARATOR
Intervention: Combined randomized groups (epoetin alfa-epbx and epoetin alfa)
Number of subjects: 1425
Study 32734207 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined long-term safety studies group
Number of subjects: 1425
Study 32734207 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa-epbx and epoetin alfa
Number of subjects: 1425
Study 32734226 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intensive nonsurgical periodontal treatment
Number of subjects: 51
Study 32734226 — intervention group
Group type: COMPARATOR
Intervention: Rescue treatment for progressive disease
Number of subjects: 51
Study 32734238 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Number of subjects: 493
Study 32734238 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 493
Study 32734246 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (resistance and aerobic exercise using exercise bands) with monthly consultations and 4 support calls over 12 weeks
Number of subjects: 36
Study 32734246 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 36
Study 32734246 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (intervention group)
Number of subjects: 36
Study 32734251 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based care (monthly sessions over 6 months)
Number of subjects: 60
Study 32734251 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 32734251 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based care (for adolescents)
Number of subjects: 60
Study 32734299 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Disorder (PD) patients who are smokers
Number of subjects: 143
Study 32734299 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Disorder (PD) patients who are non-smokers
Number of subjects: 143
Study 32734299 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls who are smokers
Number of subjects: 143
Study 32734299 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls who are non-smokers
Number of subjects: 143
Study 32734347 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic food consumption (23.3%)
Number of subjects: 34193
Study 32734347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate organic food consumption
Number of subjects: 34193
Study 32734347 — intervention group
Group type: EXPERIMENTAL
Intervention: High conventional fruits and vegetable intake
Number of subjects: 34193
Study 32734347 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest organic food consumption (31.5%)
Number of subjects: 34193
Study 32734347 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters with varying organic food proportions
Number of subjects: 34193
Study 32734597 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 4674
Study 32734597 — intervention group
Group type: COMPARATOR
Intervention: Pentosan polysulfate (PPS)
Number of subjects: 4674
Study 32734597 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular blockade
Number of subjects: 4674
Study 32734695 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental adipose tissue (OMAT) in older women
Number of subjects: 71
Study 32734695 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental adipose tissue (OMAT) in older men
Number of subjects: 71
Study 32734695 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SQAT) in women
Number of subjects: 71
Study 32734695 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein content of ER alpha and ERβ
Number of subjects: 71
Study 32734695 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous inflammatory gene expression
Number of subjects: 71
Study 32735048 — intervention group
Group type: EXPERIMENTAL
Intervention: CLL International Prognostic Index (CLL-IPI)
Number of subjects: 3307
Study 32735048 — intervention group
Group type: EXPERIMENTAL
Intervention: Barcelona-Brno score
Number of subjects: 3307
Study 32735048 — intervention group
Group type: EXPERIMENTAL
Intervention: MDACC 2007 index score
Number of subjects: 3307
Study 32735111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation with beetroot juice
Number of subjects: 0
Study 32735111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite supplementation
Number of subjects: 0
Study 32735111 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 0
Study 32735641 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd) with autologous stem cell transplantation (ASCT)
Number of subjects: 76
Study 32735641 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd) with ASCT
Number of subjects: 76
Study 32735836 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg twice per week for 2 weeks, followed by 1 week off)
Number of subjects: 25
Study 32735836 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor
Number of subjects: 25
Study 32736411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg QD
Number of subjects: 0
Study 32736511 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL surgery (n=64), performed a mean of 5 days after injury
Number of subjects: 153
Study 32736511 — intervention group
Group type: COMPARATOR
Intervention: No ACL surgery (n=89), with subgroups of 53 remaining nonsurgically treated, 27 having surgery within 2 years, and 9 having surgery between 3 and 21 years after injury
Number of subjects: 153
Study 32736511 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample (n=153)
Number of subjects: 153
Study 32736543 — intervention group
Group type: EXPERIMENTAL
Intervention: hsRDT
Number of subjects: 0
Study 32736543 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP
Number of subjects: 0
Study 32736543 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 0
Study 32736543 — intervention group
Group type: COMPARATOR
Intervention: cRDT
Number of subjects: 0
Study 32736788 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory working time scheduling software
Number of subjects: 9000
Study 32736788 — intervention group
Group type: COMPARATOR
Intervention: Traditional scheduling
Number of subjects: 9000
Study 32736826 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 1205
Study 32736826 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased severity of hypoxaemia at time of decision-to-cannulate
Number of subjects: 1205
Study 32736936 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 481
Study 32737003 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX6 with cetuximab (500 mg/m2 biweekly)
Number of subjects: 57
Study 32737076 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to parental age at onset (AAO) in sporadic Alzheimer disease (AD)
Number of subjects: 290
Study 32737087 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly subcutaneous BUP-XR injections administered by a healthcare practitioner at intervals of 28 days (-2/+14 days) after a minimum of 7 days on 8-32 mg of sublingual buprenorphine (±naloxone)
Number of subjects: 0
Study 32737087 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly subcutaneous BUP-XR injections
Number of subjects: 0
Study 32737088 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention between prescribers and ASP leaders to reinforce proper use of novel antibiotics.
Number of subjects: 0
Study 32737116 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Hypoxia
Number of subjects: 0
Study 32737116 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32737209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal CT testing at week 0
Number of subjects: 560
Study 32737209 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with azithromycin or doxycycline
Number of subjects: 560
Study 32737209 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous clearance of oropharyngeal CT
Number of subjects: 560
Study 32737209 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visits between weeks 4 and 12
Number of subjects: 560
Study 32737209 — intervention group
Group type: COMPARATOR
Intervention: Women not tested at week -1
Number of subjects: 560
Study 32737707 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction (RVD) defined as right ventricular ejection fraction < 47% in HFpEF patients
Number of subjects: 183
Study 32737707 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint of death or HF hospitalization in HFpEF patients
Number of subjects: 183
Study 32737707 — intervention group
Group type: EXPERIMENTAL
Intervention: RVD as assessed by CMR
Number of subjects: 183
Study 32737707 — intervention group
Group type: EXPERIMENTAL
Intervention: RVD as an independent predictor of adverse outcomes
Number of subjects: 183
Study 32737707 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexed extracellular volume
Number of subjects: 183
Study 32737707 — intervention group
Group type: EXPERIMENTAL
Intervention: E/E' ratio
Number of subjects: 183
Study 32737717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib (60 mg) and Ipatasertib (200 mg) in Arm A
Number of subjects: 66